Bespoke Extracts, Inc. Reports Third Quarter 2025 Results – The Joint Company Scales Colorado Production and Margin Leadership
Rhea-AI Summary
Bespoke Extracts (OTCQB: BSPK) reported record Q3 2025 results for the quarter ended September 30, 2025, driven by its The Joint Company pre-roll business.
Key metrics: Revenue $467,945 (+68.6% YoY, +19.8% QoQ); Gross margin 50.0% (up ~860 bps YoY); GAAP net loss $78,088 (72% improvement YoY); Pre-roll production 209,600 units (+81% YoY).
Outlook: Q4 2025 revenue guide $425,000–$500,000; expect ~50% blended gross margin; two new company-owned brands launching in Q4; evaluating expansion into Massachusetts and New York.
Positive
- Revenue +68.6% year-over-year to $467,945
- Gross margin 50.0%, up ~860 basis points YoY
- GAAP net loss improved 72% versus Q3 2024
- Pre-roll production +81% year-over-year to 209,600 units
Negative
- Cash declined to $16,743 from $60,305 at year-end 2024
- Total current liabilities increased to $1,872,581
- Total liabilities rose to $2,891,081, widening deficit
- Stockholders' deficit of $2,595,508 remains significant
News Market Reaction 1 Alert
On the day this news was published, BSPK gained 15.15%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AURORA, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (OTCQB: BSPK), operating as The Joint Company, today announced record results for the quarter ended September 30, 2025 — marking its strongest operational and financial performance to date.
“We’re not chasing the market — we’re building it,” said Hunter Garth, President of Bespoke Extracts. “Our Colorado business continues to prove that disciplined execution, brand trust, and smart manufacturing can win even in a contracting cannabis market. Q3 was a turning point. We produced more pre-rolls, earned strong margins, and expanded our reach — all while holding the line on overhead costs.”
Third Quarter 2025 Highlights
- Record Revenue:
$467,945 , up19.8% from Q2 2025 and68.6% year-over-year. - Gross Margin:
50.0% , up 860 basis points versus the prior year, driven by material, labor, and packaging efficiencies. - Net Loss Improvement: GAAP net loss narrowed to
$78,088 , a72% improvement from Q3 2024. - Record Production: 209,600 pre-rolls produced during the quarter — up
81% year-over-year.
Management Commentary
“Our 2025 strategic plan is delivering results, with demonstrable progress on revenue growth, distribution, and branded products,” said Michael Feinsod, Bespoke Chairman and CEO. “Our flexibility to adapt to changing market conditions in our core pre-roll business has allowed us to succeed this year in Colorado, setting us apart from many other participants.”
“We’ve built each of our brands brick by brick in one of the toughest cannabis markets in the country,” said Garth. “The fact that we can grow revenue by approximately
“This is what operational excellence looks like — continual improvement through iteration, data, and pride in the craft.”
“These Q3 results are a testament to the resilience and innovation at the core of The Joint Company,” said Michael Feinsod. “Our team's focus on efficiency and quality has not only driven record growth but also positioned us for scalable expansion. We're excited about the pipeline ahead and confident in delivering sustained value to shareholders.”
Financial Highlights
| Results of Operations | For the Three Months Ended | For the Nine Months Ended | |||||||||||||||||||
| September 30, 2025 | September 30, 2024 | % Change | June 30, 2025 | % Change | September 30, 2025 | September 30, 2024 | % Change | ||||||||||||||
| Revenue | $ | 467,945 | $ | 277,471 | 68.6 | % | $ | 390,553 | 19.8 | % | $ | 1,121,657 | $ | 816,062 | 37.4 | % | |||||
| Gross Profit | $ | 234,175 | $ | 114,995 | 103.6 | % | $ | 197,499 | 18.6 | % | $ | 542,453 | $ | 323,693 | 67.6 | % | |||||
| Gross Margin | 50.0 | % | 41.4 | % | 50.6 | % | 48.4 | % | 39.7 | % | |||||||||||
| Operating Expenses | $ | 288,066 | $ | 377,463 | -23.7 | % | $ | 359,457 | -19.9 | % | $ | 1,003,640 | $ | 1,139,207 | -11.9 | % | |||||
| Net loss | $ | (78,088 | ) | $ | (275,613 | ) | -71.7 | % | $ | (205,106 | ) | -61.9 | % | $ | (543,715 | ) | $ | (850,626 | ) | -36.1 | % |
| Basic and diluted shares outstanding | 11,249,959 | 10,635,068 | 11,153,220 | 11,185,821 | 10,327,972 | ||||||||||||||||
| EPS | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.02 | ) | $ | (0.05 | ) | $ | (0.08 | ) | ||||||
Building from the Ground Up
Fourth Quarter 2025 Outlook
- Revenue: Projected between
$425,000 and$500,000 , up41% –66% year-over-year, driven by continued demand for Fresh Joints and expansion of Doobskis and Dutch Blunts. - Gross Margin: The company expects to maintain approximately
50% blended gross margins across product lines through disciplined cost management and increased production throughput. - Innovation: Two new Company owned brands are set to launch in Q4, designed to capture adjacent market segments with highly competitive price-to-quality positioning.
- Expansion: Bespoke continues to evaluate opportunities to replicate The Joint Company model in additional regulated markets, including Massachusetts and New York.
- The company’s core brand, Fresh Joints, continues to lead Colorado’s pre-roll category in quality and volume growth. Meanwhile, new launches, Doobskis and Dutch Blunts gained meaningful traction with retail partners, creating diversified revenue streams and establishing The Joint Company as a multi-brand pre-roll house.
“We’re turning a single-state success story into a scalable blueprint,” Garth added. “Our aim is simple — to control the pre-roll category through quality, efficiency, and culture. What started as a manufacturing facility in Aurora is now a system that can be replicated across markets.”
| Bespoke Extracts, Inc. Consolidated Balance Sheets (Unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash | $ | 16,743 | $ | 60,305 | ||||
| Accounts receivable, net | 103,532 | 57,276 | ||||||
| Prepaid expense | 12,895 | 15,150 | ||||||
| Inventory, net | 63,662 | 32,526 | ||||||
| Total current assets | 196,832 | 165,257 | ||||||
| Furniture and equipment | 24,051 | 31,342 | ||||||
| License | 10,000 | 10,000 | ||||||
| Right of Use Asset | 52,690 | 140,489 | ||||||
| Deposits | 12,000 | 12,000 | ||||||
| Total assets | $ | 295,573 | $ | 359,088 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 1,392,869 | $ | 958,276 | ||||
| Note payable | 25,000 | 20,000 | ||||||
| Advances - related party | 66,872 | 66,872 | ||||||
| Operating lease liability | 52,650 | 73,523 | ||||||
| Notes payable -- secured (Net of discount of | 335,190 | - | ||||||
| Total current liabilities | 1,872,581 | 1,118,671 | ||||||
| Long-Term liabilities | ||||||||
| Notes payable -- secured (Net of discount of | - | 241,351 | ||||||
| Notes payable | 169,000 | 169,000 | ||||||
| Note payable - related party | 849,500 | 849,500 | ||||||
| Long-Term Operating Lease Liability | - | 72,504 | ||||||
| Total liabilities | 2,891,081 | 2,451,026 | ||||||
| Commitments and contingencies (Note 10) | ||||||||
| Stockholders' Deficit | ||||||||
| Preferred stock, par value | - | - | ||||||
| Series C Convertible Preferred Stock, | - | - | ||||||
| Common stock, | 11,251 | 11,151 | ||||||
| Common stock to issue 6,478 shares | - | - | ||||||
| Additional paid-in capital | 24,341,072 | 24,301,027 | ||||||
| Accumulated deficit | (26,947,831 | ) | (26,404,116 | ) | ||||
| Total stockholders' deficit | (2,595,508 | ) | (2,091,938 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 295,573 | $ | 359,088 | ||||
| See the notes to the condensed consolidated financial statements included in the Company’s 10Q filing. | ||||||||
| Bespoke Extracts, Inc. Consolidated Statements of Operations (Unaudited) | ||||||||||||||||
| For the three months ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Sales | $ | 467,945 | $ | 277,471 | $ | 1,121,657 | $ | 816,062 | ||||||||
| Cost of products sold | 233,770 | 162,476 | 579,204 | 492,369 | ||||||||||||
| Gross Profit | 234,175 | 114,995 | 542,453 | 323,693 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative expenses | 260,228 | 361,393 | 911,006 | 1,035,137 | ||||||||||||
| Professional fees | 27,838 | 16,070 | 92,634 | 104,070 | ||||||||||||
| Total operating expenses | 288,066 | 377,463 | 1,003,640 | 1,139,207 | ||||||||||||
| Loss from operations | (53,891 | ) | (262,468 | ) | (461,187 | ) | (815,514 | ) | ||||||||
| Other income / (expenses) | ||||||||||||||||
| Interest expense | (24,197 | ) | (13,145 | ) | (82,528 | ) | (35,112 | ) | ||||||||
| Total other (expense) / income | (24,197 | ) | (13,145 | ) | (82,528 | ) | (35,112 | ) | ||||||||
| Loss before income tax | (78,088 | ) | (275,613 | ) | (543,715 | ) | (850,626 | ) | ||||||||
| Provision for income tax | - | - | - | - | ||||||||||||
| Net Loss | $ | (78,088 | ) | $ | (275,613 | ) | $ | (543,715 | ) | $ | (850,626 | ) | ||||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||||||||||||||||
| Basic and Diluted | 11,249,959 | 10,635,068 | 11,185,821 | 10,327,972 | ||||||||||||
| NET LOSS PER COMMON SHARE OUTSTANDING | ||||||||||||||||
| Basic and Diluted | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.05 | ) | $ | (0.08 | ) | ||||
| See the notes to the condensed consolidated financial statements included in the Company’s 10Q filing. | ||||||||||||||||
About Bespoke Extracts, Inc.
Bespoke Extracts, Inc. (OTCQB: BSPK) is a Nevada corporation operating through its wholly-owned subsidiary, Bespoke Extracts Colorado, LLC. The company develops and manufactures branded and white-label cannabis products for the regulated U.S. market. Its flagship platform, The Joint Company, produces pre-rolls and infused products distributed across licensed Colorado dispensaries. The company currently manufactures under its owned brands FreshJoints, Doobskis, DutchBlunts and Sweet Joints.
For more information, visit: www.bespokeextracts.com
Email: info@bespokeextracts.com
Forward-Looking Statement
This release contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially from those expressed due to market conditions, regulatory changes, and other risks described in Bespoke’s filings with the SEC. The company undertakes no obligation to update forward-looking statements, except as required by law.
FAQ
What were Bespoke Extracts (BSPK) Q3 2025 revenue and growth rates?
How did Bespoke Extracts' gross margin change in Q3 2025 (BSPK)?
What was Bespoke Extracts' net loss in Q3 2025 and how did it compare to Q3 2024 (BSPK)?
What guidance did Bespoke give for Q4 2025 revenue and margins (BSPK)?
How many pre-rolls did The Joint Company produce in Q3 2025 (BSPK)?
Is Bespoke Extracts planning market expansion and new product launches (BSPK)?
